Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers
- PMID: 27689066
- PMCID: PMC5031901
- DOI: 10.1016/j.prnil.2016.04.002
Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers
Abstract
Background: Prostate cancer (PCa) diagnosis requires improvement with the aid of more accurate biomarkers. Postejaculate urethral washings (PEUW) could be a physiological equivalent to urine obtained following rectal prostatic massage, the current basis for the prostate cancer antigen 3 (PCA3) test. The aim of this study was to investigate if PEUW contained prostate-based material, evidenced by the presence of prostate specific antigen (PSA), and to evaluate the diagnostic performance of PEUW-based biomarkers.
Methods: Male patients referred for elevated serum PSA or abnormal digital rectal examination provided ejaculate and PEUW samples. PSA, PCA3, and β2-microglobulin (β2M) were quantified in ejaculate and PEUW and compared with absolute and clinically significant (according to D'Amico criteria) PCa presence, as determined by biopsies. Diagnostic performance was determined and compared with serum PSA using receiver operating characteristic analysis.
Results: From 83 patients who provided PEUW samples, paired analysis with ejaculate samples was possible for 38 patients, while analysis in an unpaired, extended cohort was possible for 62 patients. PSA and PCA3 were detected in PEUW, normalized to β2M, and PCA3:PSA was calculated. In predicting absolute PCa status, PCA3:β2M in ejaculate [area under the curve (AUC) 0.717] and PEUW (AUC 0.569) were insignificantly better than PCA3:PSA (AUC 0.668 and 0.431, respectively) and comparable with serum PSA (AUC 0.617) with similar trends observed for the extended cohort. When considering clinically significant PCa presence, serum PSA in the comparison (AUC 0.640) and extended cohorts (AUC 0.665) was comparable with PCA3: β2M (AUC 0.667) and PCA3:PSA (AUC 0.605) in ejaculate, with lower estimates for PEUW in the comparison (PCA3: β2M AUC 0.496; PCA3:PSA AUC 0.342) and extended (PCA3: β2M AUC 0.497; PCA3:PSA AUC 0.469) cohorts. The statistical analysis was limited by sample size.
Conclusion: PEUW contains prostatic material, but has limited diagnostic accuracy when considering cell-derived DNA analysis. PCA3-based markers in ejaculate are comparable to serum PSA and digital rectal examination-urine markers.
Keywords: Biomarker; Ejaculate; Prostate Cancer; Prostate Cancer Antigen 3; Prostate Specific Antigen; mRNA.
Similar articles
-
Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.Prostate. 2015 Apr 1;75(5):539-49. doi: 10.1002/pros.22942. Epub 2015 Jan 18. Prostate. 2015. PMID: 25597828
-
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.Eur Urol. 2016 Jul;70(1):45-53. doi: 10.1016/j.eururo.2015.04.039. Epub 2015 May 16. Eur Urol. 2016. PMID: 25985884 Free PMC article.
-
A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.BJU Int. 2012 Jun;109(11):1627-35. doi: 10.1111/j.1464-410X.2011.10584.x. Epub 2011 Sep 21. BJU Int. 2012. PMID: 21939492 Clinical Trial.
-
Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.Adv Exp Med Biol. 2015;867:277-89. doi: 10.1007/978-94-017-7215-0_17. Adv Exp Med Biol. 2015. PMID: 26530372 Review.
-
PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer.Chin J Cancer Res. 2016 Feb;28(1):65-71. doi: 10.3978/j.issn.1000-9604.2016.01.05. Chin J Cancer Res. 2016. PMID: 27041928 Free PMC article. Review.
Cited by
-
Un_targeted Metabolomics Study of Three Matrices: Seminal Fluid, Urine, and Serum to Search the Potential Indicators of Prostate Cancer.Front Mol Biosci. 2022 Mar 4;9:849966. doi: 10.3389/fmolb.2022.849966. eCollection 2022. Front Mol Biosci. 2022. PMID: 35309505 Free PMC article.
-
Prostate cancer biomarkers: Are we hitting the mark?Prostate Int. 2016 Dec;4(4):130-135. doi: 10.1016/j.prnil.2016.07.002. Epub 2016 Jul 29. Prostate Int. 2016. PMID: 27995111 Free PMC article. Review.
-
Long noncoding RNA PCA3 contributes to the progression of choriocarcinoma by acting as a ceRNA against miR-106b.Int J Clin Exp Pathol. 2019 May 1;12(5):1609-1617. eCollection 2019. Int J Clin Exp Pathol. 2019. PMID: 31933978 Free PMC article.
-
A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer.Int J Mol Sci. 2017 Jun 16;18(6):1281. doi: 10.3390/ijms18061281. Int J Mol Sci. 2017. PMID: 28621736 Free PMC article.
-
The Non-Coding Transcriptome of Prostate Cancer: Implications for Clinical Practice.Mol Diagn Ther. 2017 Aug;21(4):385-400. doi: 10.1007/s40291-017-0271-2. Mol Diagn Ther. 2017. PMID: 28299719 Free PMC article. Review.
References
-
- Gardiner R.A., Chambers S.K., Williams S.G., Yaxley J., Samaratunga H., Frydenberg M. Prostate cancer—part one: detection. In: De Groot L.J., Beck-Peccoz P., Chrousos G., Dungan K., Grossman A., Hershman J.M., editors. Endotext. MDText.com, Inc.; South Dartmouth (MA): 2000.
-
- Hori S., Blanchet J.S., McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int. 2013;112:717–728. - PubMed
-
- Parekh D.J., Punnen S., Sjoberg D.D., Asroff S.W., Bailen J.L., Cochran J.S. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015;68:464–470. - PubMed
-
- Hamoen E.H., de Rooij M., Witjes J.A., Barentsz J.O., Rovers M.M. Use of the prostate imaging reporting and data system (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: a diagnostic meta-analysis. Eur Urol. 2015;67:1112–1121. - PubMed
-
- Ceci F., Uprimny C., Nilica B., Geraldo L., Kendler D., Kroiss A. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42:1284–1294. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous